The current recommendation for the laboratory confirmation of Lyme disease is serology-based diagnostics. Specifically, a standardized two-tiered testing (STTT) algorithm is applied that utilizes a first-tier immunofluorescence assay or enzyme immunoassay (EIA) that, if the result is positive or equivocal, is followed by second-tier immunoblotting. Despite the standardization and performance achievements, STTT is considered technically complex and subjective, as well as insensitive for early acute infection. These issues have prompted development of novel algorithms and testing platforms. In this study, we evaluated the performance of several commonly used assays for STTT. Several modified two-tiered testing (MTTT) algorithms, including a 2-EIA algorithm and modified criteria for second-tier IgG immunoblots, were also evaluated. All tests were performed on sera from a recently available, well-defined archive of positive-and negative-control patients. Our study demonstrates differences in the results between individual first-and second-tier tests, although the overall agreement of the different STTT algorithms used was strong. In addition, the MTTT algorithm utilizing 2-EIAs was found to be equivalent to all STTT algorithms tested, with agreement ranging from 94 to 97%. The 2-EIA MTTT algorithm slightly enhanced sensitivity in early disease compared to the STTT algorithms evaluated. Furthermore, these data add to the mounting evidence that a 2-EIA-based MTTT algorithm, where immunoblotting is replaced by the C6 EIA, performs as well or better than STTT.
S
erologic testing has been the mainstay of laboratory diagnostics for Lyme disease for over 20 years. To date in the United States, serologic tests are the only U.S. Food and Drug Administration (FDA) 510(k)-cleared diagnostic tests for Lyme disease (1) . Standardization of serologic testing for Lyme disease occurred in 1994, when attendees of the Second National Conference on Serologic Diagnosis of Lyme Disease (Dearborn, MI) determined that a two-tiered algorithm, optimized for specificity and the highest sensitivity, was most appropriate for Lyme disease laboratory diagnosis (2) . The standard two-tiered testing (STTT) algorithm utilizes a first-tier immunofluorescence assay (IFA) or enzyme immunoassay (EIA) that, if the result is positive or equivocal, is followed by a second-tier immunoblot (IgM and/or IgG). The interpretation criteria for a positive immunoblot requires that at least two of three or at least five of ten bands be considered positive for IgM and IgG reactivity, respectively. Further, it was recommended that patients only be tested by IgM immunoblotting if their duration of illness is 30 days or less. STTT and interpretation criteria continue to be recommended by the Centers for Disease Control and Prevention (CDC) for laboratory confirmation of Lyme disease (2) .
Several dozen individual first-and second-tier diagnostic tests have been FDA 510(k) cleared and are commercially available. Most first-tier tests use either Borrelia burgdorferi whole-cell sonicate (WCS), whole proteins, or a peptide in an EIA platform to detect patients' antibodies to these B. burgdorferi antigens. As firsttier tests, they are designed to have a higher sensitivity and a lower specificity than the second-tier tests. All FDA-cleared second-tier tests are immunoblots, wherein antigens are physically separated or resolved from each other, and antibody to each antigen is distinctly assessed. Depending on the composition of antigens in first-and second-tier tests, the results have differing levels of interdependence; similar antigen preparations will generate results with greater interdependence than differing antigen preparations. According to these precepts and principles, the overall specificity is increased by adhering to the two-tier approach, whereas sensitivity is not.
The limitations of STTT have been thoroughly discussed in the scientific literature (3, 4) . Most limitations are associated with the second-tier immunoblotting and include subjectivity when scoring the assay and false-positive results when using IgM immunoblots (5) . Thus, researchers have explored the use of alternative serologic testing strategies. In order to remove the subjective human reader from the process, several manufacturers have developed densitometric immunoblot scanners and software to interpret the data. Another approach to improve serology utilizes an antigen that is more specific than the WCS preparation in the EIA, either as a stand-alone test or as a first-tier test. The C6 peptide of the "Vmp-like sequence, expressed" (VlsE) is an example of the latter and has been analyzed extensively (6, 7) . The C6 EIA displays higher sensitivity as a stand-alone test than STTT and avoids the complexity and subjectivity of second-tier immunoblots; however, it has not achieved the same level of specificity as STTT. At present, no single serologic test has attained or surpassed the combined sensitivity and specificity of STTT.
Additional attempts to increase the sensitivity of early Lyme disease detection have assessed several modified two-tiered testing (MTTT) algorithms. These include a 2-EIA algorithm (no immunoblotting) and two-tier testing in which the second-tier IgG immunoblot banding criteria differ from those of STTT (8, 9) . All of these MTTT strategies avoid the use of IgM immunoblots and, in general, demonstrate slightly enhanced early disease detection and equivalent or slightly reduced specificity compared to STTT.
In this study, we utilized samples from the recently available Lyme Serum Repository (LSR) (10) to compare the performances of STTT and MTTT algorithms. In addition, multiple first-and second-tier tests from differing commercial manufacturers were used, and their results were compiled individually. The results of this study corroborate previous findings indicating that a MTTT approach, wherein a 2-EIA algorithm consisting of a WCS EIA as the first-tier test, followed by the C6 EIA as the second-tier test, offers a simplified approach with enhanced sensitivity in early disease, equivalent levels of sensitivity in later stages of disease, and specificity equivalent to that of STTT for diagnosing Lyme disease. In addition, the data provided by this study can be used for comparative purposes by investigators developing improved or novel diagnostic assays for Lyme disease.
MATERIALS AND METHODS
Patient samples. The sera used in this study are from the CDC LSR and were previously described (10) . Briefly, the LSR contains serum samples from well-documented Lyme disease patients and control groups. The Lyme disease sera (n ϭ 124) are from patients that have early Lyme disease with a characteristic erythema migrans (EM) rash (acute-and convalescent-phase serum samples) (n ϭ 78) (stage 1), Lyme neuroborreliosis (n ϭ 10) (stage 2), Lyme carditis (n ϭ 7) (stage 2), or Lyme arthritis (n ϭ 29) (stage 3). The control sera (n ϭ 347) are from patients with fibromyalgia (n ϭ 31), infectious mononucleosis (n ϭ 30), multiple sclerosis (n ϭ 22), rheumatoid arthritis (n ϭ 21), severe periodontitis (n ϭ 20), syphilis (n ϭ 20), and healthy donors from regions where Lyme disease is endemic (n ϭ 101) and nonendemic (n ϭ 102). All negative controls did not have a previous known exposure to B. burgdorferi. Exposure to other Borrelia species is unknown. Institutional review board approval was granted by the CDC for the testing of these samples.
Serologic tests. All LSR samples were coded, randomized, and then tested by the VIDAS Lyme IgM and IgG polyvalent WCS EIA (bioMérieux, Inc., Durham, NC), the C6 B. burgdorferi (Lyme) enzymelinked immunosorbent assay (ELISA; Immunetics, Boston, MA), the Marblot IgM and IgG immunoblot assays (MarDx Diagnostics, Inc., Carlsbad, CA), and the Borrelia ViraStripe IgM and IgG assay (plus VlsE on the IgG immunoblot; Viramed, Biotech AG, Germany). All serologic tests were performed according to the manufacturer's instructions, and immunoblot reactive bands were identified on the basis of manufacturerprovided calibration samples. An EIA equivocal result was treated as a positive result. All samples were tested by all assays regardless of their reactivity in any assay or the duration of the donor's illness. Immunoblots were read visually (Marblot and ViraStripe) and by a densitometer (ViraStripe). For visual reads, immunoblots were scored as positive or negative by three individuals, and the interpretations were compared. If two of three reads agreed, the consensus read was accepted as final. If the reads of all three individual disagreed, a consensus read was determined by all three readers. Immunoblot bands read by densitometer were considered positive when the intensity of the band was Ն60% of the cutoff control for IgM and Ն85% of the cutoff control band for IgG. These thresholds were recommended by the manufacturer and have been published (11) .
Immunoblot interpretive criteria. All immunoblot reactivity was interpreted according to the standardized CDC criteria (2) and several modified criteria (8) . Under the CDC criteria, for the IgM or IgG immunoblots to be positive, at least two of three specific bands or at least five of ten specific bands had to meet the test intensity thresholds, respectively. Under modified criteria, IgG reactivity to 11 bands was scored in the ViraStripe immunoblots that included VlsE (Viramed). Specifically, the modified criteria used were as follows: (i) VlsE reactivity alone, (ii) at least three of eleven specific bands, and (iii) at least five of eleven specific bands (8) .
Two-tier testing and interpretive criteria. A variety of two-tier testing algorithms (STTT and MTTT) were evaluated ( Table 1) . As noted above, in STTT the second-tier immunoblot utilized the CDC-recommended IgM and IgG blot criteria (2) . According to these recommendations, IgM immunoblots were not considered in the final interpretation when serum samples were collected from patients with Ͼ30 days of illness. In the immunoblot-based MTTT, the second-tier IgG immunoblot banding criteria was altered as described in the previous paragraph, and the use of IgM immunoblots was omitted. The 2-EIA-based MTTT algorithm uti- 
RESULTS
First-tier testing. Two FDA 510(k)-cleared first-tier EIAs (VIDAS and C6) were performed ( Table 2 ). As expected (9), the VIDAS EIA (WCS) resulted in a higher sensitivity for Lyme disease (68% for acute early Lyme disease with EM, 89% for convalescent-phase early Lyme disease with EM, 100% for Lyme carditis, and 100% for Lyme arthritis) compared to the C6 EIA (58% for acute early Lyme disease with EM, 84% for convalescent-phase early Lyme disease with EM, 86% for Lyme carditis, and 100% for Lyme arthritis). The only exception to this trend was for samples from patients diagnosed with Lyme neuroborreliosis in which the VIDAS EIA displayed 90% sensitivity compared to 100% using the C6 EIA (Table 2) . When comparing the specificities of these two assays, the VIDAS EIA had a higher cross-reactivity than the C6 EIA, yielding false-positive results in sera from patients with rheumatoid arthritis (90% specificity), syphilis (15% specificity), multiple sclerosis (82% specificity), and infectious mononucleosis (47% specificity), as well as in sera from healthy donors from regions where Lyme disease is endemic (91% specificity) and nonendemic (95% specificity). Comparatively, the C6 EIA was crossreactive with sera from patients with syphilis (90% specificity), multiple sclerosis (95% specificity), and infectious mononucleosis (87% specificity) and in sera from healthy donors from regions where Lyme disease is endemic (99% specificity) and nonendemic (96% specificity).
In addition to testing the VIDAS EIA and C6 EIAs, VlsE striped on the ViraStripe immunoblot was analyzed as a first-tier test. The VlsE band assay was slightly less sensitive with samples for both acute-phase (50% sensitivity) and convalescent-phase (79% sensitivity) early Lyme disease patients with EM compared to the C6 EIA (58% sensitivity for acute-phase samples and 84% sensitivity for convalescent-phase samples). As expected, both assays demonstrated increased sensitivity with convalescent-phase samples compared to acute-phase samples. The C6 and VlsE sensitivities were the same for the other Lyme disease groups (Lyme neuroborreliosis, Lyme carditis, and Lyme arthritis). For specific control groups, the VlsE immunoblot assay demonstrated increased specificity compared to the C6 EIA (100% specificity for patients with multiple sclerosis and infectious mononucleosis and 98% specificity for healthy donors from regions of nonendemicity). The VlsE immunoblot assay was slightly less specific when controls from regions of endemicity were tested (96% specificity for the VlsE band assay compared to 99% specificity for the C6 EIA).
The overall agreement among the three tests (VIDAS EIA, C6 EIA, and the VlsE band) was determined to be 81% (Table 3 ). The majority of the disagreement between the tests was due to the higher positivity observed with the VIDAS EIA compared to the C6 EIA and the VlsE band. The overall agreement between the C6 EIA and the VlsE band assay was 93%.
Second-tier testing. Second-tier testing was performed using immunoblots produced by two different manufacturers, MarDx (Marblot) and Viramed (ViraStripe plus VlsE) (see Table 1 ). The Marblot immunoblots and ViraStripe immunoblots without the striped VlsE band are FDA 510(k) cleared, but the ViraStripe immunoblot with the VlsE band is not. However, the ViraStripe plus VlsE is commercially available in Europe for the laboratory diagnostic testing for Lyme disease.
IgM results. ViraStripe IgM immunoblots read visually gave higher or equivalent sensitivities (45, 74, 100, 71, and 52% for acute early Lyme disease with EM, convalescent-phase early Lyme disease with EM, Lyme neuroborreliosis, Lyme carditis, and Lyme arthritis, respectively) compared to those of Marblot immunoblots (35, 53, 100, 57, and 31% for acute early Lyme disease with EM, convalescent-phase early Lyme disease with EM, Lyme neuroborreliosis, Lyme carditis, and Lyme arthritis, respectively) (Table 2). When other diseases were tested for IgM reactivity, the Marblot immunoblot had a slightly higher overall specificity (92%) compared to the ViraStripe immunoblot (90%). Interestingly, both immunoblot types had the highest cross-reactivity with samples from patients with infectious mononucleosis. Overall, ViraStripe IgM immunoblots (read visually) were 92% specific, whereas Marblot immunoblots were 98% specific for healthy controls from areas of endemicity and nonendemicity combined. The agreement between the two IgM immunoblots read visually was 87% (Table 3) , with the most disagreement attributed to a positive result using the ViraStripe immunoblot and a negative result with the Marblot immunoblot.
IgG results. IgG Marblot and ViraStripe immunoblots read visually had an overall agreement of 96% (Table 3) . Marblot IgG immunoblot sensitivities were 20, 37, 30, 57, and 100%, and ViraStripe IgG sensitivities (read visually) were 18, 32, 40, 71, and 100% for acute early Lyme disease, convalescent-phase early Lyme disease, Lyme neuroborreliosis, Lyme carditis, and Lyme arthritis, respectively ( Table 2 ). The specificities for Marblot and ViraStripe IgG immunoblots read visually were higher than for the IgM immunoblots when testing samples from patients with other diseases (100% for Marblot and 99% for ViraStripe) and healthy donors (99% for Marblot and 98% for ViraStripe). When comparing IgM and IgG reactivities in healthy controls (from areas of endemicity and nonendemicity), a larger difference in specificity was observed with IgM immunoblots than with IgG immunoblots. As expected, IgG immunoblots had a higher specificity when testing healthy controls than IgM immunoblots.
IgM and/or IgG results. The sensitivities for IgM and/or IgG positivity were similar between Marblot and ViraStripe immunoblots read visually (Table 2) . Marblot sensitivities were 45, 71, 100, 86, and 100%, and ViraStripe sensitivities were 53, 79, 100, 100, and 100% for acute early Lyme disease, convalescent-phase early Lyme disease, Lyme neuroborreliosis, Lyme carditis, and Lyme arthritis, respectively. Specificities were similar for fibromyalgia (97% by Marblot and 94% by ViraStripe), severe periodontitis (100% by both Marblot and ViraStripe), and healthy controls from areas of nonendemicity (98% by Marblot and 95% by ViraStripe) but differed slightly for rheumatoid arthritis (95% by Marblot and 86% by ViraStripe), syphilis (90% by Marblot and 95% by ViraStripe), multiple sclerosis (91% by Marblot and 100% by (40) 27 (68) 23 (58) 20 (50) 14 (35) 8 (20) 18 (45) 18 (45) 7 (18) 21 (53) 21 (53) 5 (13) 22 (55) Convalescent (38) 34 (89) 32 (84) 30 (79) 20 (53) 14 (37) 27 (71) 28 (74) 12 (32) 30 (79) 29 (76) (10) 9 (90) 10 (100) 10 (100) 10 (100) 3 (30) 10 (100) 10 (100) 4 (40) 10 (100) 9 (90) 4 (40) 9 (90) Carditis (7) 7 (100) 6 (86) 6 (86) 4 (57) 4 (57) (9) 1 (1) 4 (4) 2 (2) 2 (2) 4 (4) 12 (12) 4 (4) 16 (16) 11 (11) 3 (3) 14 (14) Nonendemic (102) 5 (5) 4 (4) 2 (2) 2 (2) 0 (0) 2 (2) 4 (4) 1 (1) 5 (5) 1 (1) 0 (0) 1 (1) All negative controls 53 (15) 12 (3) 8 (2) 15 (4) 2 (1) 17 (5) 31 (9) 7 (2) 37 (11) 29 (8) 4 (1) 32 (9) a WCS, whole-cell sonicate; EIA, enzyme immunoassay; VIDAS, a Lyme IgM and IgG polyvalent assay (bioMérieux, Inc., Durham, NC). These data have been previously reported (10) . b C6 EIA, B. burgdorferi Lyme ELISA (Immunetics, Inc., Boston, MA). c VlsE band striped onto the Borrelia B31 ViraStripe immunoblot (Viramed Biotech AG, Munich, Germany) and read visually. d The Marblot data were reported previously (10) . Positive IgM immunoblot results were reported regardless of duration of illness prior to specimen collection. ViraStripe), infectious mononucleosis (83% by Marblot and 67% by ViraStripe), and healthy controls from areas of endemicity (96% by Marblot and 84% by ViraStripe). Overall, the sensitivity was slightly higher when using ViraStripe immunoblots compared to Marblot immunoblots; however, the specificity was slightly lower for the ViraStripe immunoblots.
Visual versus densitometer reads (Viramed immunoblots).
Visual and densitometer reads were performed using the ViraStripe immunoblots. The overall percentages of agreement between the two reads for IgM and IgG immunoblots were 92 and 97%, respectively (Table 3 ). There was no difference in the percentages of samples that were called positive or negative in a comparison of visual reads and densitometer reads for IgM immunoblots (4% were scored positive by densitometer that were called negative by visual read, and 3% were scored negative by densitometer that were scored positive by visual read). For IgG immunoblots, the percentage of reads that were scored negative by densitometer and scored positive by visual read (2%) was higher than the percentage of reads that were scored positive by densitometer and scored negative by visual read (0.6%).
Banding results. Positive bands were compared between Marblot (visual reads) and ViraStripe (visual and densitometer reads) immunoblots. The results are summarized in Table S1 in the supplemental material. The band reactivities for Lyme disease patients (all stages) tested by IgM or IgG immunoblotting were similar between the two immunoblot manufacturers evaluated with a notable exception of the reactivities for bands 39 (IgM and IgG immunoblots) and 66 (IgG immunoblots). In IgM immunoblots for Lyme disease patients, bands 41 (48 to 69% positive) and 23 (60 to 63% positive) were the most often scored. Similarly, in both IgG immunoblot systems, bands 41, 23, and 18 were among the most commonly scored bands. In ViraStripe IgM immunoblots, band 39 was reactive with 58 and 60% of samples from Lyme disease patients by visual and densitometric reads, respectively. In contrast, only 24% of samples from Lyme patients were reactive with band 39 in the IgM Marblot system. This trend was inverted in IgG immunoblots. Specifically, Marblot immunoblot band 39 was reactive for samples from 52% of Lyme disease patients, whereas the ViraStripe immunoblot was reactive for samples from only 34 and 29% of Lyme disease patients in visual and densitometric reads, respectively. Also, a notable difference in reactivity between the two immunoblot systems was the IgG reactivity to band 66. Marblot immunoblot reactivity to band 66 was 41%, while the ViraStripe immunoblot reactivities were 69 and 60% (visual and densitometric reads, respectively).
Overall, 6 to 26% of samples from the other disease groups were positive for any given IgM band and 0 to 58% of samples produced a reactive IgG band. Healthy control reactivity to any band ranged from 1 to 27% and 0 to 60% for IgM and IgG, respectively. The percent reactivity of healthy controls for at least one IgM band or at least one IgG band ranged from 13 to 32% or 36 to 72%, respectively. When the immunoblot types (Marblot and ViraStripe) were compared, there was an overall higher rate of reactivity to at least one band by healthy controls when using the ViraStripe immunoblot.
Standard two-tiered testing (STTT). The CDC-recommended STTT (2) was performed using first-tier assays consisting of EIAs (VIDAS or C6), followed by second-tier IgM and IgG immunoblotting (Marblot or ViraStripe). The results for the various twotiered combinations tested are summarized in Table 4 . When the VIDAS EIA was fixed as a first-tier test, ViraStripe immunoblots were more sensitive (69 to 73%) than Marblot immunoblots (67%), but the specificities were comparable (98% for Marblot immunoblots and 97% for ViraStripe immunoblots). Similar sensitivities (68% for Marblot immunoblots and 68 to 71% for ViraStripe immunoblots) and specificities (99% for both immunoblot types) were seen between the two immunoblot types when the C6 EIA was fixed as the first-tier test. When Marblot immunoblots were fixed as the second-tier test, the C6 EIA and the VIDAS EIA had similar sensitivities (68 and 67%, respectively) and specificities (99 and 98%, respectively). When ViraStripe immunoblots were fixed as the second-tier test, the sensitivities for all Lyme disease samples using VIDAS and C6 EIAs in the first tier were comparable (69 to 73% when using the VIDAS EIA and 68 to 71% when using the C6 EIA). Slightly increased sensitivities were observed when the VIDAS EIA (48% sensitivity for both visual and densitometer reads) was used as the first-tier test for acute early Lyme disease samples compared to when the C6 EIA (43 to 45% sensitivity) was used as the first-tier test. The specificity observed when ViraStripe immunoblots were fixed was lower when using the VIDAS EIA (97%) as first-tier test compared to the C6 EIA (99%). Overall, the specificities of the various two-tiered combinations were similar, except in the evaluation of infectious mononucleosis samples. Specifically, this group of patient samples had a higher IgM false positivity for any of the combinations that included the VIDAS EIA as the first tier or ViraStripe immunoblots as the second tier.
The agreements between two-tiered combinations were 94 and 96%, respectively, when VIDAS and C6 EIAs were fixed as the first tier and the variable was the second-tier immunoblot (VIDAS/ Marblot versus VIDAS/ViraStripe visual versus VIDAS/ViraStripe densitometer and C6/Marblot versus C6/ViraStripe visual versus C6/ViraStripe densitometer) ( Table 5 ). When STTT combinations were compared when the variable was VIDAS or C6 EIAs as the first-tier test and the second-tier immunoblot was fixed (VIDAS/Marblot versus C6/Marblot, VIDAS ViraStripe visual versus C6/ViraStripe visual, and VIDAS/ViraStripe densitometer versus C6/ViraStripe densitometer), the agreement ranged from 96 to 99% (Table 5) . (48) 16 (40) 19 (48) 19 (48) 16 (40) 18 (45) 17 (43) Convalescent (38) 30 (79) e 28 (74) 23 (61) 26 (68) 24 (63) 24 (63) 26 (68) 24 (63) Early Lyme neuroborreliosis or Lyme carditis, stage 2 Neuroborreliosis (10) 9 (90) 9 (90) 9 (90) 9 (90) 8 (80) 9 (90) 9 (90) 9 (90) Carditis (7) 6 (86) 6 (86) 6 (86) 7 (100) 7 (100) 6 (86) 6 (86) 6 (86) Late Lyme disease (stage 3) Lyme arthritis (29) 29 (100) 29 (100) 29 (100) 29 (100) 28 (97) 29 (100) 29 (100) 28 (97) All Lyme disease 94 (76) 91 (73) 83 (67) 90 (73) 86 (69) 84 (68) 88 (71) 84 ( (10) 7 (23) 8 (27) 1 (3) 3 (10) 2 (7) Healthy controls Endemic (101) 1 (1) h 1 (1) 2 (2) 4 (4) 3 (3) 1 (1) 1 (1) 1 (1) Nonendemic (102) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (1) 1 (1) 0 (0) All negative controls 6 (2) 1 (0) 6 (2) 11 (3) 12 (3) 3 (1) 5 (1) 3 (1) a An EIA result was considered positive if the result was positive or equivocal. Only four positive 2-EIA results had an equivocal result for one EIA: one sample in the early Lyme with EM acute group, one in the early Lyme with EM convalescent group, one in the Lyme carditis group, and one in the syphilis group. b VlsE result was obtained using a visual read of the ViraStripe immunoblot. c These data have been reported previously (10) . d No statistical differences were observed between the sensitivities of the VIDAS/C6 2-EIA MTTT and STTT algorithms (P values ranged from 0.22 to 1.00) when acute-phase early Lyme disease samples were tested (see Table S3 in the supplemental material). e A statistical difference (P Ͻ 0.05) was only observed between the sensitivities obtained by the VIDAS/C6 2-EIA MTTT algorithm and the VIDAS/Marblot visual read STTT algorithm when convalescent-phase early Lyme disease samples were tested (see Table S3 in the supplemental material). f One of the two positive samples by the 2-EIA VIDAS/C6 algorithm was also determined to be positive by the VIDAS/Marblot visual read algorithm. g One of the two samples that was determined to be positive by the 2-EIA VIDAS/C6 MTTT algorithm was also determined to be positive by all STTT algorithms tested. The second sample that was determined to be positive by the 2-EIAVIDAS/C6 MTTT algorithm was also determined to be positive by four of the STTT algorithms tested. h The sample that was determined to be positive by the 2-EIA VIDAS/C6 MTTT algorithm was also determined to be positive by all other STTT algorithms tested.
Modified two-tiered testing. (i) MTTT algorithms using only IgG immunoblotting as the second tier. The sensitivities and
specificities of the two MTTT algorithms using modified IgG immunoblot criteria were compared to those of all STTT algorithms tested (Table 4; see also Table S2 in the supplemental material). The VIDAS EIA was used as the first-tier assay. The first modification of the second tier required reactivity to at least three of eleven bands for positivity. Overall, the sensitivity observed with this modification (69%) was similar to those of the STTT algorithms VIDAS/ViraStripe (69% sensitivity) and C6/ViraStripe (68% sensitivity) for all stages of Lyme disease combined. The specificity of this algorithm was slightly lower (96%) than those of the other MTTT and STTT algorithms (97 to 100%). The specificity of this MTTT algorithm for healthy controls from areas of endemicity was on the lower end at 96% compared to 96 to 99% for this group by the STTT algorithms.
The second modified IgG immunoblot criteria required VlsE reactivity for early Lyme disease acute-and convalescent-phase samples, Lyme carditis, Lyme neuroborreliosis, and negative controls for second-tier positivity and reactivity of at least five of eleven bands for late disease (Lyme arthritis) second-tier positivity. This MTTT algorithm performed slightly better (73% sensitivity) than the STTT algorithms VIDAS/ViraStripe and C6/ ViraStripe (sensitivity of 68 to 69%) tested for the detection of Lyme disease samples (see Table S2 in the supplemental material). The specificity by this approach was the highest at 100%.
(ii) 2-EIA (VIDAS/C6) and VIDAS/VlsE. The sensitivity and specificity of the MTTT 2-EIA algorithm (VIDAS EIA, followed by the C6 EIA) was tested and compared to those of all STTT algorithms (Table 4; see also Table S2 in the supplemental material). For all samples, the 2-EIA MTTT algorithm was equivalent or significantly better (P Ͻ 0.05) than any STTT algorithm (see Table  S3 in the supplemental material). The 2-EIA MTTT algorithm demonstrated the highest sensitivity (76%) for all Lyme disease groups combined (Table 4) . When only early Lyme acute-phase samples were evaluated, the sensitivity of the 2-EIA MTTT algorithm was not significantly better than those of any of the STTT algorithms performed, but the observed percentage differences (2.5 to 10.0%) for all comparisons favored the 2-EIA MTTT algorithm over all STTT algorithms (see Table S3 in the supplemental material). For early Lyme disease convalescent-phase samples, the 2-EIA MTTT algorithm (sensitivity of 79%) significantly (P Ͻ 0.05) outperformed the VIDAS/Marblot and was equivalent to the other STTT algorithms (sensitivities for all STTT algorithms ranged from 61 to 68%) (Table 4; see also Tables S2 and S3 in the supplemental material). The specificity of the 2-EIA MTTT algorithm was 100% for all negative-control groups except syphilis (90% specificity), multiple sclerosis (95% specificity), infectious mononucleosis (93% specificity), and healthy controls from areas of endemicity (99% specificity). For all samples tested, the specificity of the 2-EIA MTTT demonstrated a specificity of 98% compared to 97 to 99% for STTT algorithms and 96 to 100% for the other MTTT algorithms tested.
The sensitivities and specificities of the 2-EIA MTTT algorithm were also compared to those obtained using the VlsE immunoblot band instead of the C6 EIA. There was a high agreement of 97% between the 2-EIA MTTT and the VIDAS/VlsE band algorithms (Table 5 ). When the 2-EIA MTTT and the VIDAS/VlsE band algorithms were compared to the various STTT algorithms (EIA/ immunoblot), their agreement ranged from 94 to 97%.
DISCUSSION
The purpose of this study was to obtain a more comprehensive evaluation of the overall performance of two-tiered testing for Lyme disease using multiple first-and second-tier tests with wellcharacterized positive and negative controls. We used the LSR that is a unique serum panel consisting of 471 sera that were acquired from patients with various stages of Lyme disease, as well as from patients and donors of multiple negative-control groups (10) . Because the samples used in this study are available for investigators to use for novel laboratory diagnostic development, the information provided here is meant to be used as baseline data for comparative purposes. Previous published work with this panel assessed the sensitivity and specificity using single first-and second-tier assays and did not evaluate other tests or alternate algorithms (10) . Overall, there were differences in sensitivity and specificity between the first-and second-tier tests evaluated. First-tier testing was more sensitive but less specific when the VIDAS WCS EIA was used than when the C6 EIA and VlsE immunoblotting were used. However, when second-tier immunoblotting was applied, the overall sensitivities and specificities did not differ greatly between the STTT algorithms tested, with the exception of specificity with infectious mononucleosis samples. This patient group displayed a poor specificity when the VIDAS EIA was used as a first tier, followed by IgM ViraStripe immunoblotting as the second tier, and reiterated some of the specificity issues with both test types (WCS and IgM immunoblotting).
Improper use of IgM immunoblots and their relative poor specificity compared to IgG blots have been reported previously (5) . Several studies have attempted to avoid these shortcomings by alternate approaches in which IgM immunoblots are not used, including altered IgG immunoblot criteria and two EIA algorithms (8, 9) . Generally, the sensitivities observed here were slightly higher when using ViraStripe immunoblots compared to Marblot immunoblots; however, the specificity was slightly lower for the ViraStripe immunoblots. It should be noted that changes in the intensity cutoff used by the densitometer to read the ViraStripe immunoblots might affect the overall sensitivity and specificity. Our results showed high agreement (97%) between IgG immunoblots that were read visually and with a densitometer, but this agreement dropped to 92% for IgM immunoblots. In this study, we used densitometer cutoffs that are in line with the manufacturer's recommendations and that have been previously published (11); however, increasing the cutoff intensity for reading IgM immunoblots by densitometer may increase specificity but also lower sensitivity.
Banding patterns between manufactured immunoblots for Lyme patients and negative controls have not been thoroughly documented. When using the LSR samples to compare the two immunoblot types (Marblot and ViraStripe) and reading methods (visual and densitometer), we observed differences in the levels of band positivity between the two immunoblot types. However, there was little difference in interpretation of the same immunoblot (ViraStripe) read visually or with a densitometer. The discrepancy observed between the two reading methods was primarily due to differences in the IgM immunoblots. Similarly, the discrepancies in band positivity caused a large difference in the overall results for IgM immunoblots (the overall agreement between Marblot and ViraStripe blots read visually was 87%) compared to IgG immunoblots (the overall agreement between Marblot and ViraStripe blots read visually was 96%). These results underscore some of the limitations of IgM immunoblots. Further, the assessment of reactive bands when using healthy controls demonstrated that 13 to 32% and 36 to 72% of healthy individuals would have at least one reactive band by IgM or IgG, respectively. This is important for clinicians and patients to know when interpreting immunoblot data and to understand why the recommended criteria of at least two of three IgM bands and at least five of ten IgG bands are used for positivity.
Regardless of the tests and test combinations used, the sensitivity of the STTT algorithms for early acute Lyme disease remained quite low (40 to 48%). As expected, a higher sensitivity was achieved for convalescent-phase early Lyme disease samples (61 to 68%), as well as for samples from patients with disseminated forms of Lyme disease (neurologic and cardiac Lyme) (80 to 100%) and late Lyme disease (Lyme arthritis) (97 to 100%). It should be noted that the number of patients with neurologic and cardiac Lyme disease used in this study was low and did not allow for statistical analyses to be performed when used as independent groups. The data for these two groups, however, do show the expected trend in serologic reactivity (increase in sensitivity compared to that for early Lyme patients without these two manifestations) and were therefore included in this study to provide comparative information on these two more complicated manifestations of early Lyme disease.
Two MTTT algorithms that maintain the use of IgG immunoblots were evaluated (8) , and although one MTTT algorithm (VIDAS/VlsE for stages 1 and 2 or at least five of eleven immunoblot bands for stage 3) performed well (73% sensitivity and 100% specificity), having two separate criteria for positivity that are dependent on the stage of infection is difficult and appropriate testing would require clinical information to ensure that the proper testing was performed. The second MTTT evaluated that maintains the use of immunoblotting used three of eleven IgG bands to call a sample positive. This MTTT algorithm had the lowest specificity (96%) of the MTTT and STTT algorithms tested and did not provide a higher sensitivity compared to the other MTTT or STTT algorithms evaluated. Due to the complexity associated with Lyme disease immunoblots and the subjectivity associated with their scoring, an MTTT algorithm that applies two EIAs has been proposed (9) . We tested the 2-EIA approach consisting of the VIDAS EIA, followed by the C6 EIA, that was previously introduced by Branda et al. (9) and found that, overall, the 2-EIA approach demonstrated a sensitivity (76% overall) and a specificity (98% overall) comparable to those of the STTT algorithms (the overall sensitivity ranged from 67 to 73%, and the overall specificity ranged from 97 to 99%), with slightly better sensitivity in the detection of early disease acute-phase samples (50% for the 2-EIA algorithm compared to 40 to 48% for the STTT algorithms) and convalescent-phase samples (79% for the 2-EIA algorithm compared to 61 to 68% for the STTT algorithms). These results were consistent with previous findings (9) and suggested that a 2-EIA algorithm is a simplified and objective alternative to the STTT algorithm. Further testing to better understand the consistencies and inconsistencies when using a 2-EIA algorithm is under way with larger sample sizes. In addition, when the VIDAS-VlsE band approach was tested, the results obtained were also similar to those of the STTT algorithms.
Although novel approaches for the diagnosis of Lyme disease are currently being developed that include serology-based and non-serology-based assays (12) (13) (14) (15) , for now, serologic testing, and specifically an STTT algorithm using an EIA (or IFA), followed by immunoblotting, remains the CDC-recommended diagnostic testing method for patients with Lyme disease (2) . The findings presented here demonstrate the strengths and weaknesses of STTT using well-characterized serum samples and controls and also support previous findings that a 2-EIA-based MTTT algo-rithm for serologic diagnostic testing for Lyme disease may be a beneficial addition to the currently recommended laboratory diagnostic algorithm for Lyme disease. In addition to its simplicity and the removal of subjective aspects of visually read immunoblots, the 2-EIA was shown to outperform STTT in patients with early disease presenting with EM. Although serologic testing for this type of Lyme disease patient is not necessary for diagnosis, reference performance data are important to both test developers and clinicians. Further, these data form a basis for the comparative analysis of early patients presenting without EM or with atypical EM, an important patient group and one which is often difficult to document. Beyond early Lyme disease patients, the data presented here and the continued availability of the same sample set sera from the CDC enable comparisons of other and newly developed serologic tests and algorithms.
